CA2977539A1 - Sterol regulatory element-binding proteins (srebps) inhibitors - Google Patents
Sterol regulatory element-binding proteins (srebps) inhibitors Download PDFInfo
- Publication number
- CA2977539A1 CA2977539A1 CA2977539A CA2977539A CA2977539A1 CA 2977539 A1 CA2977539 A1 CA 2977539A1 CA 2977539 A CA2977539 A CA 2977539A CA 2977539 A CA2977539 A CA 2977539A CA 2977539 A1 CA2977539 A1 CA 2977539A1
- Authority
- CA
- Canada
- Prior art keywords
- thiophen
- piperidin
- tert
- methanone
- butylpyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN615/DEL/2015 | 2015-03-04 | ||
| IN615DE2015 | 2015-03-04 | ||
| IN640DE2015 | 2015-03-09 | ||
| IN640/DEL/2015 | 2015-03-09 | ||
| PCT/US2016/020802 WO2016141258A1 (en) | 2015-03-04 | 2016-03-04 | Sterol regulatory element-binding proteins (srebps) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2977539A1 true CA2977539A1 (en) | 2016-09-09 |
Family
ID=55586426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2977539A Abandoned CA2977539A1 (en) | 2015-03-04 | 2016-03-04 | Sterol regulatory element-binding proteins (srebps) inhibitors |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10189826B2 (enExample) |
| EP (1) | EP3265457A1 (enExample) |
| JP (1) | JP2018507235A (enExample) |
| CA (1) | CA2977539A1 (enExample) |
| WO (1) | WO2016141258A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10328064B2 (en) | 2014-12-23 | 2019-06-25 | Fgh Biotech, Inc. | Compositions of fatostatin based heterocyclic compounds and uses thereof |
| EP3265088A1 (en) | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance |
| ES2912921T3 (es) | 2016-04-29 | 2022-05-30 | Fgh Biotech Inc | Compuestos de pirazol disustituidos para el tratamiento de enfermedades |
| US11339142B2 (en) | 2016-09-07 | 2022-05-24 | Fgh Biotech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
| JP2021512160A (ja) | 2018-01-29 | 2021-05-13 | カピュラス セラピューティクス リミテッド ライアビリティ カンパニー | ６員の中央環を含むｓｒｅｂｐ阻害剤 |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020132700A1 (en) | 2018-12-21 | 2020-06-25 | Fgh Biotech Inc. | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof |
| WO2020159889A1 (en) * | 2019-01-28 | 2020-08-06 | Capulus Therapeutics, Llc | Srebp inhibitors comprising a thiophene central ring |
| WO2021097123A1 (en) * | 2019-11-13 | 2021-05-20 | Capulus Therapeutics, Llc | Thiophene compounds with cyclic amides, and uses thereof |
| KR20220128335A (ko) * | 2019-11-13 | 2022-09-20 | 카풀루스 테라퓨틱스, 엘엘씨 | 티오펜 중심 고리를 포함하는 srebp 저해제 |
| WO2021154735A1 (en) * | 2020-01-27 | 2021-08-05 | Capulus Therapeutics, Llc | Srebp inhibitors comprising a thiophene central ring |
| EP4185584A1 (en) * | 2020-07-24 | 2023-05-31 | Capulus Therapeutics, LLC | Srebp inhibitors comprising a thiophene central ring |
| CN112225728A (zh) * | 2020-08-18 | 2021-01-15 | 四川农业大学 | 一种多取代苯甲酰胺化合物及其制备方法和应用 |
| CN117050074B (zh) * | 2022-05-05 | 2025-08-12 | 中国药科大学 | 一类吡啶联咪唑并吡啶化合物及其制备方法与用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96891A0 (en) * | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| US6291514B1 (en) | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
| NZ506507A (en) | 1998-02-09 | 2003-08-29 | Dimensional Pharm Inc | Heteroaryl amidine, methylamidine or guanidine derivatives useful as urokinase inhibitors |
| IL149872A0 (en) | 1999-12-16 | 2002-11-10 | Schering Corp | Substituted imidazole neuropeptide y y5 receptor antagonists |
| AR029686A1 (es) | 2000-06-22 | 2003-07-10 | Dow Agrosciences Llc | Compuestos de 2-(3,5-disustituido-4-piridil)-4-(tienilo, tiazolilo o arilfenil)-1,3-oxazolina, composiciones y metodos para el control de insectos o acaros y/o plantas utilizando dichos compuestos |
| EP1628666B1 (en) | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
| JP2008545767A (ja) * | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用 |
| MX2007015729A (es) | 2005-06-09 | 2008-02-21 | Schering Plough Ltd | Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida. |
| AU2006272978B2 (en) | 2005-07-26 | 2012-06-07 | Bial - Portela & Ca, S.A. | Nitrocatechol derivatives as COMT inhibitors |
| CA2620179C (en) | 2005-08-16 | 2013-10-29 | Icagen, Inc. | Inhibitors of voltage-gated sodium channels |
| US8229106B2 (en) | 2007-01-22 | 2012-07-24 | D.S.P. Group, Ltd. | Apparatus and methods for enhancement of speech |
| AU2008214095B2 (en) | 2007-02-02 | 2014-07-10 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
| JP2010521450A (ja) * | 2007-03-16 | 2010-06-24 | アクテリオン ファーマシューティカルズ リミテッド | Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体 |
| EP2250165B1 (en) | 2007-12-21 | 2018-07-25 | Merck Serono S.A. | Triazole oxadiazoles derivatives |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| CA2786424A1 (en) | 2010-01-08 | 2011-07-14 | Ruga Corporation | Raf kinase inhibitors |
| WO2012084678A1 (en) | 2010-12-23 | 2012-06-28 | Syngenta Participations Ag | Novel imidazoles useful as plant fungicides |
| JP2014062047A (ja) | 2011-01-21 | 2014-04-10 | Taisho Pharmaceutical Co Ltd | ピラゾール誘導体 |
| GB201116017D0 (en) | 2011-09-16 | 2011-10-26 | Univ Surrey | Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors |
| UY34539A (es) | 2011-12-23 | 2013-06-28 | Millennium Pharm Inc | Heteroarilos y usos de los mismos |
| WO2013110007A1 (en) | 2012-01-18 | 2013-07-25 | The Trustees Of Columbia University In The City Of New York | USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION |
| WO2014199164A1 (en) | 2013-06-12 | 2014-12-18 | Ampla Pharmaceuticals, Inc. | Diaryl substituted heteroaromatic compounds |
| WO2014210389A1 (en) | 2013-06-26 | 2014-12-31 | Rett Syndrome Research Trust | Rett syndrome and treatments therefore |
| AU2014312245B2 (en) | 2013-08-28 | 2018-12-13 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
| EP3265088A1 (en) | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance |
-
2016
- 2016-03-04 US US15/553,622 patent/US10189826B2/en not_active Expired - Fee Related
- 2016-03-04 CA CA2977539A patent/CA2977539A1/en not_active Abandoned
- 2016-03-04 WO PCT/US2016/020802 patent/WO2016141258A1/en not_active Ceased
- 2016-03-04 EP EP16710893.5A patent/EP3265457A1/en not_active Withdrawn
- 2016-03-04 JP JP2017546186A patent/JP2018507235A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016141258A1 (en) | 2016-09-09 |
| JP2018507235A (ja) | 2018-03-15 |
| US20180051013A1 (en) | 2018-02-22 |
| EP3265457A1 (en) | 2018-01-10 |
| US10189826B2 (en) | 2019-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10189826B2 (en) | Heterocyclic compounds and methods of use | |
| CA2584666C (en) | Pyrimidine derivative condensed with a non-aromatic ring | |
| US9303023B2 (en) | Pyrazole and imidazole derivatives useful as orexin antagonists | |
| JP2023529908A (ja) | Ｂｒｍ標的化化合物及び関連する使用方法 | |
| WO2012068546A1 (en) | Heterocycle amines and uses thereof | |
| CA2935071A1 (en) | Piperidine-dione derivatives | |
| JP2023109962A (ja) | Ｐｒｃ２阻害剤 | |
| DK3038622T3 (en) | HETEROCYCLIC RELATIONS AND PROCEDURES FOR USE | |
| BR112016012146B1 (pt) | Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
| CA2666973A1 (en) | Indole compound having a glucokinase activating action | |
| JP2023529884A (ja) | コラーゲン１翻訳阻害剤及びその使用方法 | |
| WO2024026484A2 (en) | Cdk2 inhibitors and methods of using the same | |
| US9102673B2 (en) | Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors | |
| US20220370431A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| EP4463452B1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| KR102607510B1 (ko) | 무스카린 m1 수용체 양성 알로스테릭 조절제로서의 피롤로-피리다진 유도체 | |
| US12404283B2 (en) | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | |
| EP4547672A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| WO2023245137A1 (en) | Slow skeletal troponin activators | |
| US20260069602A1 (en) | Compounds, compositions, and methods | |
| CA2991404A1 (en) | Imide derivatives and use thereof as medicine | |
| KR20230155834A (ko) | Ido/tdo 이중 저해용 화합물 및 이를 포함하는 약학적 조성물 | |
| WO2024193640A1 (zh) | Cdk抑制剂 | |
| JP2025510009A (ja) | Ｒｉｐ１調節物質、その調製、及び使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20210907 |